Erratum: Small Molecule Inhibitors of Aurora-A Induce Proteasomal Degradation of N-Myc in Childhood Neuroblastoma (Cancer Cell (2013) 24(1) (78–89) (S1535610813002328) (10.1016/j.ccr.2013.05.005));Small Molecule Inhibitors of Aurora-A Induce Proteasomal Degradation of N-Myc in Childhood Neuroblastoma

Cancer Cell

Volumn 24, Issue 1, 2013, Pages 75-89

  Brockmann, Markus ^a   Poon, Evon ^b   Berry, Teeara ^b   Carstensen, Anne ^a   Deubzer, Hedwig E ^c   Rycak, Lukas ^d   Jamin, Yann ^c   Thway, Khin ^b   Robinson, Simon P ^b   Roels, Frederik ^e   Witt, Olaf ^c   Fischer, Matthias ^e   Chesler, Louis ^b   Eilers, Martin ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d Institute for Molecular Biology and Tumor Research   (Germany)

^e UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 [[9 CHLORO 7 (2,6 DIFLUOROPHENYL) 5H PYRIMIDO[5,4 D][2]BENZAZEPIN 2 YL]AMINO]BENZOIC ACID; ALISERTIB; AURORA A KINASE; FBXW7 ENZYME; MYC PROTEIN; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHILDHOOD CANCER; COMPLEX FORMATION; CONTROLLED STUDY; HUMAN; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION;

EID: 84880042989     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2016.07.002     Document Type: Erratum

References (40)

1. Beltran H., Rickman D.S., Park K., Chae S.S., Sboner A., MacDonald T.Y., Wang Y., Sheikh K.L., Terry S., Tagawa S.T., et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011, 1:487-495.
2. Bouchard C., Dittrich O., Kiermaier A., Dohmann K., Menkel A., Eilers M., Lüscher B. Regulation of cyclin D2 gene expression by the Myc/Max/Mad network: Myc-dependent TRRAP recruitment and histone acetylation at the cyclin D2 promoter. Genes Dev. 2001, 15:2042-2047.
3. Brodeur G.M., Seeger R.C., Schwab M., Varmus H.E., Bishop J.M. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984, 224:1121-1124.
4. Bruggeman S.W., Valk-Lingbeek M.E., van der Stoop P.P., Jacobs J.J., Kieboom K., Tanger E., Hulsman D., Leung C., Arsenijevic Y., Marino S., van Lohuizen M. Ink4a and Arf differentially affect cell proliferation and neural stem cell self-renewal in Bmi1-deficient mice. Genes Dev. 2005, 19:1438-1443.
5. Chanthery Y.H., Gustafson W.C., Itsara M., Persson A., Hackett C.S., Grimmer M., Charron E., Yakovenko S., Kim G., Matthay K.K., Weiss W.A. Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma. Science translational medicine 2012, 4. 115ra113.
6. Chen X., Xu H., Yuan P., Fang F., Huss M., Vega V.B., Wong E., Orlov Y.L., Zhang W., Jiang J., et al. Integration of external signaling pathways with the core transcriptional network in embryonic stem cells. Cell 2008, 133:1106-1117.
7. Delmore J.E., Issa G.C., Lemieux M.E., Rahl P.B., Shi J., Jacobs H.M., Kastritis E., Gilpatrick T., Paranal R.M., Qi J., et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011, 146:904-917.
8. Dodson C.A., Kosmopoulou M., Richards M.W., Atrash B., Bavetsias V., Blagg J., Bayliss R. Crystal structure of an Aurora-A mutant that mimics Aurora-B bound to MLN8054: insights into selectivity and drug design. Biochem. J. 2010, 427:19-28.
9. Faisal A., Vaughan L., Bavetsias V., Sun C., Atrash B., Avery S., Jamin Y., Robinson S.P., Workman P., Blagg J., et al. The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma invivo. Mol. Cancer Ther. 2011, 10:2115-2123.
10. Gullberg M., Fredriksson S., Taussig M., Jarvius J., Gustafsdottir S., Landegren U. A sense of closeness: protein detection by proximity ligation. Curr. Opin. Biotechnol. 2003, 14:82-86.
11. Hatton B.A., Knoepfler P.S., Kenney A.M., Rowitch D.H., de Alborán I.M., Olson J.M., Eisenman R.N. N-myc is an essential downstream effector of Shh signaling during both normal and neoplastic cerebellar growth. Cancer Res. 2006, 66:8655-8661.
12. Herold S., Wanzel M., Beuger V., Frohme C., Beul D., Hillukkala T., Syvaoja J., Saluz H.P., Haenel F., Eilers M. Negative regulation of the mammalian UV response by Myc through association with Miz-1. Mol. Cell 2002, 10:509-521.
13. Horn V., Thélu J., Garcia A., Albigès-Rizo C., Block M.R., Viallet J. Functional interaction of Aurora-A and PP2A during mitosis. Mol. Biol. Cell 2007, 18:1233-1241.
14. Kawauchi D., Robinson G., Uziel T., Gibson P., Rehg J., Gao C., Finkelstein D., Qu C., Pounds S., Ellison D.W., et al. A mouse model of the most aggressive subgroup of human medulloblastoma. Cancer Cell 2012, 21:168-180.
15. Kim Y.H., Girard L., Giacomini C.P., Wang P., Hernandez-Boussard T., Tibshirani R., Minna J.D., Pollack J.R. Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification. Oncogene 2006, 25:130-138.
16. Manfredi M.G., Ecsedy J.A., Meetze K.A., Balani S.K., Burenkova O., Chen W., Galvin K.M., Hoar K.M., Huck J.J., LeRoy P.J., et al. Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc. Natl. Acad. Sci. USA 2007, 104:4106-4111.
17. Manfredi M.G., Ecsedy J.A., Chakravarty A., Silverman L., Zhang M., Hoar K.M., Stroud S.G., Chen W., Shinde V., Huck J.J., et al. Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel invivo pharmacodynamic assays. Clin. Cancer Res. 2011, 17:7614-7624.
18. Marumoto T., Zhang D., Saya H. Aurora-A - a guardian of poles. Nat. Rev. Cancer 2005, 5:42-50.
19. Matulonis U.A., Sharma S., Ghamande S., Gordon M.S., Del Prete S.A., Ray-Coquard I., Kutarska E., Liu H., Fingert H., Zhou X., et al. Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Gynecol. Oncol. 2012, 127:63-69.
20. Miliani de Marval P.L., Macias E., Rounbehler R., Sicinski P., Kiyokawa H., Johnson D.G., Conti C.J., Rodriguez-Puebla M.L. Lack of cyclin-dependent kinase 4 inhibits c-myc tumorigenic activities in epithelial tissues. Mol. Cell. Biol. 2004, 24:7538-7547.
21. Nilsson J.A., Keller U.B., Baudino T.A., Yang C., Norton S., Old J.A., Nilsson L.M., Neale G., Kramer D.L., Porter C.W., Cleveland J.L. Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation. Cancer Cell 2005, 7:433-444.
22. Oberthuer A., Hero B., Berthold F., Juraeva D., Faldum A., Kahlert Y., Asgharzadeh S., Seeger R., Scaruffi P., Tonini G.P., et al. Prognostic impact of gene expression-based classification for neuroblastoma. J.Clin. Oncol. 2010, 28:3506-3515.
23. Otto T., Horn S., Brockmann M., Eilers U., Schüttrumpf L., Popov N., Kenney A.M., Schulte J.H., Beijersbergen R., Christiansen H., et al. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 2009, 15:67-78.
24. Popov N., Wanzel M., Madiredjo M., Zhang D., Beijersbergen R., Bernards R., Moll R., Elledge S.J., Eilers M. The ubiquitin-specific protease USP28 is required for MYC stability. Nat. Cell Biol. 2007, 9:765-774.
25. Rakhra K., Bachireddy P., Zabuawala T., Zeiser R., Xu L., Kopelman A., Fan A.C., Yang Q., Braunstein L., Crosby E., et al. CD4(+) Tcells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell 2010, 18:485-498.
26. Seki A., Coppinger J.A., Jang C.Y., Yates J.R., Fang G. Bora and the kinase Aurora a cooperatively activate the kinase Plk1 and control mitotic entry. Science 2008, 320:1655-1658.
27. Shang X., Burlingame S.M., Okcu M.F., Ge N., Russell H.V., Egler R.A., David R.D., Vasudevan S.A., Yang J., Nuchtern J.G. Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma. Mol. Cancer Ther. 2009, 8:2461-2469.
28. Shimomura T., Hasako S., Nakatsuru Y., Mita T., Ichikawa K., Kodera T., Sakai T., Nambu T., Miyamoto M., Takahashi I., et al. MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel. Mol. Cancer Ther. 2010, 9:157-166.
29. Sjostrom S.K., Finn G., Hahn W.C., Rowitch D.H., Kenney A.M. The Cdk1 complex plays a prime role in regulating N-myc phosphorylation and turnover in neural precursors. Dev. Cell 2005, 9:327-338.
30. Sloane D.A., Trikic M.Z., Chu M.L., Lamers M.B., Mason C.S., Mueller I., Savory W.J., Williams D.H., Eyers P.A. Drug-resistant aurora A mutants for cellular target validation of the small molecule kinase inhibitors MLN8054 and MLN8237. ACS Chem. Biol. 2010, 5:563-576.
31. Sodir N.M., Swigart L.B., Karnezis A.N., Hanahan D., Evan G.I., Soucek L. Endogenous Myc maintains the tumor microenvironment. Genes Dev. 2011, 25:907-916.
32. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., Mesirov J.P. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 2005, 102:15545-15550.
33. Valentijn L.J., Koster J., Haneveld F., Aissa R.A., van Sluis P., Broekmans M.E., Molenaar J.J., van Nes J., Versteeg R. Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification. Proc. Natl. Acad. Sci. USA 2012, 109:19190-19195.
34. Weiss W.A., Aldape K., Mohapatra G., Feuerstein B.G., Bishop J.M. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J. 1997, 16:2985-2995.
35. Welcker M., Orian A., Jin J., Grim J.E., Harper J.W., Eisenman R.N., Clurman B.E. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc. Natl. Acad. Sci. USA 2004, 101:9085-9090.
36. Wenzel A., Cziepluch C., Hamann U., Schürmann J., Schwab M. The N-Myc oncoprotein is associated invivo with the phosphoprotein Max(p20/22) in human neuroblastoma cells. EMBO J. 1991, 10:3703-3712.
37. Wong D.J., Liu H., Ridky T.W., Cassarino D., Segal E., Chang H.Y. Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell 2008, 2:333-344.
38. Workman P., Aboagye E.O., Balkwill F., Balmain A., Bruder G., Chaplin D.J., Double J.A., Everitt J., Farningham D.A., Glennie M.J., et al. Guidelines for the welfare and use of animals in cancer research. Br. J. Cancer 2010, 102:1555-1577. Committee of the National Cancer Research Institute.
39. Yada M., Hatakeyama S., Kamura T., Nishiyama M., Tsunematsu R., Imaki H., Ishida N., Okumura F., Nakayama K., Nakayama K.I. Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J. 2004, 23:2116-2125.
40. Yeh E., Cunningham M., Arnold H., Chasse D., Monteith T., Ivaldi G., Hahn W.C., Stukenberg P.T., Shenolikar S., Uchida T., et al. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat. Cell Biol. 2004, 6:308-318.